Immunogen (IMGN) Misses Q1 EPS by 6c, Beats on Revenues
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Research and development support: 1.35M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development support: 1.35M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $15.04 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Stardust Power (SDST) Tops Q2 EPS by 1c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
